Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy

PACE - Pacing and Clinical Electrophysiology

Volumn 26, Issue 9, 2003, Pages 1887-1896

  Begley, David A ^a   Mohiddin, Saidi A ^a   Tripodi, Dorothy ^a   Winkler, Judith B ^a   Fananapazir, Lameh ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Cardiovascular Branch   (United States)

Author keywords

Cardiomyopathy; Genetics; Prognosis; Sudden death

Indexed keywords

ADOLESCENT; ADULT; AGED; BLOOD PRESSURE MEASUREMENT; CLINICAL FEATURE; DEFIBRILLATOR; DEVICE; DISEASE SEVERITY; EXERCISE TEST; FEMALE; FOLLOW UP; HEART ARREST; HEART ARRHYTHMIA; HEART HYPERTROPHY; HEART VENTRICLE TACHYCARDIA; HOLTER MONITORING; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMPLANTATION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOMES RESEARCH; PATIENT SELECTION; PRIMARY PREVENTION; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; SECONDARY PREVENTION; SHOCK; SITTING; SUDDEN DEATH; SURVIVAL RATE; TREATMENT INDICATION;

ADOLESCENT; ADULT; AGED; CARDIOMYOPATHY, HYPERTROPHIC; CHILD; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; FOLLOW-UP STUDIES; HEART ARREST; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; RISK ASSESSMENT; SURVIVAL RATE; TACHYCARDIA, VENTRICULAR; TIME FACTORS;

EID: 0141630291     PISSN: 01478389     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1460-9592.2003.00285.x     Document Type: Review

References (49)

1. Wigle ED, Rakowski H, Kimball BP, et al. Hypertrophic cardiomyopathy: Clinical spectrum and treatment. Circulation 1995; 92:1680-1692.
2. Fananapazir L. Hypertrophic cardiomyopathy. In Rakel and Bope (eds).: Conns Current Therapy Philadelphia, WB Saunders Company. 2001, pp. 300-304.
3. Watkins H, Rosenzweig A, Hwang D.S, et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med 1992; 326:1108-1114.
4. Fananapazir L, Advances in molecular genetics and management of hypertrophic cardiomyopathy. JAMA 1999; 281:1746-1752.
5. Schwartz K, Carrier L, Guicheney P, et al. Molecular basis of familial cardiomyopathies. Circulation 1995; 91:532-540.
6. Fananapazir L, Epstein ND. Genotype-phenotype correlations in hypertrophic cardiomyopathy: Insights provided by comparisons of kindreds with distinct and identical .-myosin heavy chain gene mutations. Circulation 1994; 89:22-32.
7. Watkins H, McKenna WJ, Thierfelder L, et al. Mutations in the genes for cardiac troponin T and α-tropomyosin hypertrophic cardiomyopathy. N Engl J Med 1995; 332:1058-1064.
8. 95 Ala) associated with mild cardiac phenotype but a high incidence of sudden death and cardiac failure. Circulation 2001; 103:65-71.
9. Raith MH, Bardy GH. Advances in implantable cardioverter-defibrillator therapy. Current Opinion in Cardiology 1994; 9:23-29.
10. O'Donoghue S, Platia, Mispireta L, et al. Safety of defibrillator therapy in patients with hypertrophic cardiomyopathy. (abstract) J Am Coll Cardiol 1994; 23:11.
11. Fananapazir L, Chang A, Epstein SE, et al. Prognostic determinants in hypertrophic cardiomyopathy: Prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophsiologic findings. Circulation 1992; 86:730-740.
12. Fananapazir L, McAreavey D, Hypertrophic cardiomyopathy: Evaluation and treatment of patients at high risk for sudden death. PACE 1997; 20 (Suppl.): 478-501.
13. Zhu D, Sun H, Hill R, et al. The value of electrophysiologic study and prophylactic implantation of cardioverter defibrillator in patients with hypertrophic cardiomyopathy. PACE 1998; 21:299-302.
14. Borggrefe M, Breithardt G. Is the implantable defibrillator indicated in patients with hypertrophic cardiomyopathy and aborted sudden death? (editorial; comment). J Am Coll Cardiol 1998; 31:1086-1088.
15. Elliott P, Sharma S, Varnava A, et al. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999; 33:1596-1601.
16. Primo J, Geelen P, Brugada J, et al. Hypertrophic cardiomyopathy: Role of the implantable cardioverter-defibrillator. J Am Coll Cardiol 1998; 31:1081-1085.
17. Hayes DL, Friedman PA. Implantable Device Therapy for Patients With Hypertrophic Cardiomyopathy. In I.E. Ovsyschcher (ed.): Cardiac Arrhythmias and Device Therapy: Results and Perspectives for the New Century. Armonk, NY: Futura Publishing Company, Inc., 2000; p. 393-399.
18. Freedman RA. Use of implantable pacemaker and implantable defibrillators in hypertrophic cardiomyopathy. Curr Opin Cardiol 2001; 16:58-65.
19. Fananapazir L, Epstein SE. Hemodynamic and electrophysiologic evaluation of patients with hypertrophic cardiomyopathy surviving cardiac arrest. Am J Cardiol 1991; 67:280-287.
20. Lehmann M, Saksena S. NASPE policy statement. Implantable cardioverter defibrillators in cardiovascular practice: Report of the policy conference of NASPE. PACE 1991; 14:969-979.
21. Gregoratos G, Cheitlin MD, Conill A, et al. ACC/AHA guidelines for implantation of cardiac pacemakers and antiarrhythmic devices: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on pacemaker implantation). J Am Coll Cardiol 1998; 31:1175-1206.
22. Maron BJ, Shen W-K, Link MS, et al. Efficacy of implantable cardioverter-defibrillator-defibrillators for prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000; 342:365-373.
23. Grace AA, Brady PA, Shapiro LM. Risk management in hypertrophic cardiomyopathy. Lancet 2001; 357:407-408.
24. McKenna WJ, Franklin RCG, Nihoyannopoulos P, et al. Arrhythmia and prognosis in infants, children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol 1988; 11:147-153.
25. Fiddler GI, Tajik AJ, Weidman WH, et al. Idiopathic hypertrophic subaortic stenosis in the young. Am J Cardiol 1978; 4:793-799.
26. McKenna W, Deanfield J, Furuqui A, et al. Prognosis in hypertrophic cardiomyopathy: Role of age and clinical, electrocardiographic and hemodynamic features. Am J Cardiol 1981; 47:53:533-538.
27. Koga Y, Itaya K, Toshima K. Prognosis in hypertrophic cardiomyopathy. Am Heart J 1984; 108:351-359.
28. McKenna WJ, Counihan PJ, Chikamori T. Sudden Death in Hypertrophic Cardiomyopathy: Identification and Management of High Risk Patients. In G. Baroldi, F. Camerini, J.F. Goodwin (eds.): Advances in Cardiomyopathies. Berlin Heidelberg, Springer-Verlag, 1990, pp. 72-80.
29. Sekiguchi M, Hongo M, Morimoto S-I, et al. Long-Term Prognosis and Treatment of Hypertrophic Cardiomyopathy. InM. Sekiguchi, PJ. Richardson (eds.): Cardiomyopathy Update 5. Prognosis and Treatment of Cardiomyopathies and Myocarditis. Tokyo, University of Tokyo Press, 1994, pp. 41-59.
30. Maron BJ, Lipson LC, Roberts WC, et al. "Malignant" hypertrophic cardiomyopathy: Identification of a subgroup of families with unusually frequent premature death. Am J Cardiol 1987; 41:1133-1140.
31. Maron BJ, Savage DD, Wolfson JK, et al. Prognostic significance of 24-hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy. A prospective study. Am J Cardiol 1981; 48:252-257.
32. McKenna WJ. England D, Doi YL, et al. Arrhythmia in hypertrophic cardiomyopathy. 1. Influence on prognosis. Br Heart J 1981; 46:168-172.
33. Spirito P, Rapezzi C, Autore C, et al. Prognosis of asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia. Circulation 1994; 90:2743-2747.
34. Spirito P, Bellone P, Harris KM, et al. Magnitude of LV hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. New Engl J Med 2000; 342:1778-1785.
35. Spirito P, Maron BJ. Relation between extent of LV hypertrophy and occurrence of sudden cardiac death in hypertrophic cardiomyopathy. J Am Coll Cardiol 1990; 15:1521-1526.
36. Elliot PM, Blanes JRG, Mahon NG, et al. Relation between severity of LV hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 2001; 357:420-424.
37. Dilsizian V, Bonow RO, Epstein E, et al. Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1993; 22:796-804.
38. Frenneaux MP, Counihan PJ, Cafario AL, et al. Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy. Circulation 1990; 82:1995-2002.
39. Sadoul N, Prasad K, Elliott PM, et al. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation 1997; 96:2987-2991.
40. Cecchi F, Maron BJ, Epstein SE. Long-term outcome of patients with hypertrophic cardiomyopathy successfully resuscitated after cardiac arrest. J Am Coll Cardiol 1989; 13:1283-1288.
41. Maron BJ, Roberts WC, McAllistair HA, et al. Sudden death in young athletes. Circulation 1980; 62:218-229.
42. Gadler F, Linde C, Daubert C, et al. for the PIC study group. Significant improvement of quality of life following atrioventricular synchronous pacing in patients with hypertrophic obstructive cardiomyopathy. Data from 1 year of follow-up. Eur Heart J 1999; 20:1044-1050.
43. Silka MJ, Kron J, Dunnigan A, et al. Sudden cardiac death and the use of implantable cardioverter-defibrillators in pediatric patients. Circulation 1993; 87:800-807.
44. Kron J, Silka MJ, Ohm OJ, et al. Preliminary experience with non-thoractomy implantable cardioverter-defibrillators in young patients. PACE 1994; 17:25-30.
45. Hamilton RM, Dorian P, Gow RM, et al. Five-year experience with implantable defibrillators in children. Am J Cardiol 1996; 77:524-526.
46. Link MS, Hill SL, Cliff DL, et al. Comparison of complications of implantable cardioverter-defibrillators in children versus adults. Am J Cardiol 1999; 83:263-256.
47. Gallik DM, Ben-Zur UM, Gross JN, et al. Lead fracture in cephalic versus subclavian approach with transvenous implantable defibrillator systems PACE 1996; 19:1089-1094.
48. Berul CI. Implantable Cardioverter Defibrillators in Pediatrics. In I.E. Ovsyschcher (ed.): Cardiac Arrhythmias and Device Therapy: Results and Perspectives for the New Century. Anmonk NY, Futura Publishing Company, Inc. 2000, pp. 217-221.
49. NASPE Policy Statement. PACE 1993; 16:1358.